<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04667182</url>
  </required_header>
  <id_info>
    <org_study_id>17420</org_study_id>
    <secondary_id>F3Z-MC-IORN</secondary_id>
    <nct_id>NCT04667182</nct_id>
  </id_info>
  <brief_title>A Study of Glucose Control in Participants With Type 1 and Type 2 Diabetes</brief_title>
  <official_title>Meal-centric Insulin Dosing for Optimized Post-Prandial Glucose Control in People Using Multiple Daily Injections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to determine whether combining meal, glucose and insulin&#xD;
      data in a web-based system will improve management of type 1 (T1D) and type 2 diabetes (T2D).&#xD;
      No study drug will be given. The study will last about 18 weeks.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study was withdrawn prior to enrolment due to business decision.&#xD;
  </why_stopped>
  <start_date type="Anticipated">January 25, 2021</start_date>
  <completion_date type="Anticipated">December 6, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 6, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Area Under the Curve (AUC) of CGM</measure>
    <time_frame>Baseline, Week 17</time_frame>
    <description>Change from Baseline in AUC of CGM</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Qualitative data from study investigators and participants</measure>
    <time_frame>Baseline through Week 17</time_frame>
    <description>Qualitative data describing experience from study investigators and participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Time-in-Range (TIR)</measure>
    <time_frame>Baseline through Week 17</time_frame>
    <description>Percent Time-in-Range defined as glucose &gt;70 and ≤180 milligrams per deciliter [mg/dL])</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial TIR</measure>
    <time_frame>Baseline through Week 17</time_frame>
    <description>Postprandial TIR is defined as TIR glucose: glucose &gt;=70 and ≤180 mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Above Range (TAR)</measure>
    <time_frame>Baseline through Week 17</time_frame>
    <description>TAR is defined as glucose &gt; 180 mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Below Range (TBR) &lt;70 mg/dL</measure>
    <time_frame>Baseline through Week 17</time_frame>
    <description>TBR is defined as glucose &lt; 70 mg/dL</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">0</enrollment>
  <condition>Type 1 Diabetes</condition>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Combined Diabetes Management Data</arm_group_label>
    <description>Participants with type 1 and type 2 diabetes will use a meal tagging application (app) and fitness tracker. They will upload these data to a web portal where they will be matched with data from their insulin pen and continuous glucose monitor (CGM). Combined data will be used as a complement to standard of care for diabetes management.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Meal-Tagging App and Web-based Portal:</intervention_name>
    <description>Meal tagging app to capture frequently eaten meals and test meals for 18 weeks.</description>
    <arm_group_label>Combined Diabetes Management Data</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Fitness Tracker</intervention_name>
    <description>Fitness tracker will be worn around the clock for 18 weeks.</description>
    <arm_group_label>Combined Diabetes Management Data</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adults with T1D and T2D&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Individuals with type 1 or type 2 diabetes for &gt;3 years by clinical diagnosis who use&#xD;
             basal insulin, in addition to at least one injection of meal time insulin per day&#xD;
&#xD;
          -  Insulin pen use for at least 3 months&#xD;
&#xD;
          -  Current use of or willingness to use Dexcom G6 at least 6 out of 7 days per week&#xD;
&#xD;
          -  A1c 6.5-9.5%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently using any form of insulin pump, including hybrid closed-loop system (e.g.,&#xD;
             Medtronic 670G)&#xD;
&#xD;
          -  Individuals requiring single insulin boluses of &gt;40 units&#xD;
&#xD;
          -  Individuals planning to follow a specific diet plan for weight loss&#xD;
&#xD;
          -  Inability to consume regular, consistent meals&#xD;
&#xD;
          -  Individuals who have had severe hypoglycemia with seizure or coma within the past 6&#xD;
             months&#xD;
&#xD;
          -  Individuals who have been hospitalized for diabetic ketoacidosis (DKA) within the past&#xD;
             6 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Boston Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina, Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 11, 2020</study_first_submitted>
  <study_first_submitted_qc>December 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2020</study_first_posted>
  <last_update_submitted>September 10, 2021</last_update_submitted>
  <last_update_submitted_qc>September 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>T1D</keyword>
  <keyword>T2D</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

